The Latest Breaking News from Hologic

Hologic is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth in the company’s bottom-line figure.

Hologic has recently outperformed in the Nasdaq, and Wall Street analysts are moderately bullish about the stock’s prospects.

Women in households earning up to £25k per annum are less health literate - and less likely to understand healthcare professionals

The WTA is pushing for advancement in women’s healthcare through its partnership with Hologic

Upgrades

'Several diversity, equity, and inclusion demographic factors already impact the global economy,' Bank of America analysts say.

Pulled from Benzinga Pro data, Hologic (NASDAQ:HOLX) posted Q2 earnings of $455.70 million, an increase from Q1 of 8.71%. Sales dropped to $1.44 billion, a 2.38% decrease between quarters.

Hologic Inc (NASDAQ:HOLX) reported Q2 FY22 sales of $1.44 billion, down 7% Y/Y, and beating the consensus Wall Street estimate for revenues of $1.29 billion. Lower sales of COVID-19 assays primarily drove a fall in sales. Hologic's global diagnostics business posted revenues of $987.1 million, down 7%. Diagnostics revenues excluding COVID-19 revenues…

Raymond James has decided to maintain its Outperform rating of Hologic (NASDAQ:HOLX) and lower its price target from $84.00 to $83.00. Shares of Hologic are trading down 2.08% over the last 24 hours, at $69.37 per share. A move to $83.00 would account for a 19.65% increase from the current…